



A Brighter Future for Mental Health

CNSX: MBIO

MINDBIO LANDMARK SLEEP RESEARCH PUBLISHED IN PRESTIGIOUS NATURE PORTFOLIO JOURNAL TRANSLATIONAL PSYCHIATRY

- **MindBio scientist's sleep research published in prestigious peer reviewed scientific journal**
- **MindBio's proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing**

Vancouver, British Columbia – 23 April, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharma company uniquely pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines is pleased to announce publication of its scientist's sleep research in the prestigious Nature portfolio journal Translational Psychiatry.

MindBio's unique investment thesis in the sector, is that small, sub-hallucinogenic doses of a psychedelic drug, MB22001 is the most scalable way to use a psychedelic medicine to treat depressive disorders globally. The Company's goal is to commercialize MB22001 as an affordable, accessible replacement to first line medications such as anti-depressants with low side effects (particularly no sexual side effects, emotional numbness, or weight gain) resulting in greater adherence to the treatment.

The sleep research accepted for publication is transformative for the treatment of depressive disorders because of the importance of sleep for maintaining good physical and mental well-being. We now know that MB22001 has a range of benefits for improving mood, energy, sleep and reducing depressive symptoms in patients suffering from depression. The sleep research from randomized controlled clinical trials, discovered participants in the treatment (MB22001) group had on average 24 minutes of extra sleep time and 8 minutes of additional REM sleep time the day after microdosing MB22001 compared to placebo in a one day on, two day off treatment protocol. Interestingly, sleep on dose days was not changed with no material difference between the treatment and placebo groups. The Company is now not only targeting depression in it's commercialization strategy for MB22001, but also addressing the adjacent negative impact on sleep commonly experienced in depression noting that the sleeping aids market is projected to reach \$118 billion in 2030 according to research published by Polaris Market Research in 2022.

Chief Executive Officer of MindBio, Justin Hanka said “Microdosing MB22001 is a disruptive treatment methodology that we know improves sleep, depression and mood and our ambition

is to develop this treatment globally at scale for affordable access to patients without the limitations and side-effects of common anti-depressants.”.

The Company currently has two Phase 2 clinical trials underway and new trials in development.

To read the published sleep research, go here: <https://www.nature.com/articles/s41398-024-02900-4>

Receive our latest updates here: <https://www.mindbiotherapeutics.com/get-updates>

Follow MindBio on LinkedIn: <https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true>

Follow CEO Justin Hanka on LinkedIn: <https://www.linkedin.com/in/justinhanka/>

For further information, please contact:

Justin Hanka, Chief Executive Officer
61 433140886
justin@mindbiotherapeutics.com

Media Inquiries

Kristina Spionjak
pr@hlthcommunications.com

About MindBio Therapeutics

MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials. MB22001 is MindBio’s lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants, has a Phase 2a clinical trial just completed microdosing in patients with Major Depressive Disorder and a Phase 2B clinical trial currently underway microdosing in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

Cautionary Note Concerning Forward-Looking Statements:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.